Mouse Anti-HBEGF Recombinant Antibody (clone HB-20) (CAT#: HPAB-0092-LS)

Figure 1 The binding activity of antibodies HA-20, HB-20, and HC-15 to active-form HB-EGF;

Figure 2 Histograms that show the binding activity of antibodies HA-20, HB-20, and HC-15 to proHB-EGF.

Figure 3 The inhibition of binding of HB-EGF to EGFR by antibodies HA-20, HB-20, and HC-15.

Figure 4 Compares the inhibition of the growth of EGFR_Ba/F3 cells by antibodies HA-20, HB-20, and HC-15.

Figure 5 The inhibition of growth of the ovarian cancer cell line RMG-1 by the antibodies HA-20, HB-20, and HC-15 in a medium containing 8% FCS;

Figure 6 The internalization-mediated activity of the HA-20, HB-20, and HC-15 antibodies to induce cell death in SKOV-3 cells (original cell line) and HB-EGF_SKOV3 cells (high HB-EGF-expressing SKOV-3 cells).

Figure 7 The binding activity of the HA-20, HB-20, and HC-15 antibodies for the HB-EGF on ES-2 cells.

Figure 8 The internalization-mediated cell death inducing activity of HA-20, HB-20, and HC-15, on ES-2 ovarian cancer cells.

Figure 9 The FACS analysis of the binding activity exhibited by various anti-HB-EGF antibodies for HB-EGF overexpressed in Ba/F3 cells; the fluorescence intensity is expressed on the vertical axis as the G-mean value.

Figure 10 The ADCC activity exhibited by various anti-HB-EGF antibodies on HB-EGF_Ba/F3 cells (upper) and the CDC activity exhibited by various anti-HB-EGF antibodies on HB-EGF_Ba/F3 cells (lower); the vertical axis shows the amount of chromium released from the cells due to ADCC-mediated or CDC-mediated cytotoxicity.